The rapid expansion of biologic drugs in recent years has led to a pressing need for the production of mAbs and Recombinant protein manufacturing and market and approval trends indicate that MAb products will continue to be a dominant biotherapeutic modality for the foreseeable future. Symbiosis has extensive experience manufacturing these class of products making them a leading CMO in this space.
Download our mAb and Recombinant Protein manufacturing capabilities sheet to find out more about how Symbiosis are well placed to support your mAb and Recombinant Protein manufacturing requirements.
Fill in your details to be added to our mailing list and receive our latest updates.
